Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ImClone swings to 3Q07 loss

IMCL reported a 3Q07 diluted loss per share of $0.01, versus EPS of $0.65 in 3Q06, due in part

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE